文献速递糖尿病肥胖与代谢综合征

儿童与青年癌症治疗后的糖尿病风险

Diabetes Risk After Treatment for Childhood and Young Adult Cancer.
PubMed 文献 · Diabetes Care · 2025-01-01

研究基于英国4238例儿童与青年癌症幸存者的注册数据,通过临床编码或HbA1c识别糖尿病,中位随访14.4年共163例(3.8%)发生糖尿病。全身照射、糖皮质激素及造血干细胞移植与糖尿病风险升高相关,异基因移植者40年累积发病率达25.7%。

要点

  • 中位随访14.4年,4238例幸存者中163例(3.8%)发生糖尿病。
  • 接受全身照射者40年糖尿病累积发病率为21.0%,未接受者为8.4%。
  • 异基因造血干细胞移植者40年累积发病率为25.7%,自体移植者为7.9%。

核心结论

  • 该医院为基础的儿童与青年癌症患者队列显示其长期糖尿病风险增加,且风险随治疗方式不同随时间变化。
  • 不同治疗间的风险差异在癌症诊断后10年即可观察到。
  • 研究结果应有助于制定风险分层的循证筛查方案。

研究设计与样本

  • 研究为基于英国癌症登记数据(n=4238)的队列研究,链接电子医疗数据库通过临床编码或HbA1c值识别糖尿病病例。
  • 采用灵活参数模型和标准化病因别累积发病率函数估计预设治疗暴露对糖尿病风险的总效应。

主要发现

  • 中位随访14.4年后,163例(3.8%)被识别为糖尿病。
  • 全身照射(TBI)随时间增加糖尿病风险,40年累积发病率为21.0%(95%CI 13.8-31.9),未接受TBI者为8.4%(95%CI 6.1-11.5)。
  • 接受糖皮质激素治疗的幸存者在癌症诊断后40年风险增加7.7%。
  • 造血干细胞移植(HSCT)幸存者风险显著更高,40年累积发病率为19.6%(95%CI 13.4-28.6),未接受HSCT者为8.2%(95%CI 6.0-11.3)。
  • 异基因HSCT患者40年糖尿病累积发病率为25.7%(95%CI 17.4-38.0),自体移植患者为7.9%(95%CI 3.3-19.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Diabetes is a potential late consequence of childhood and young adult cancer (CYAC) treatment. Causative treatments associated with diabetes have been identified in retrospective cohort studies but have not been validated in population-based cohorts. Our aim was to define the extent of diabetes risk and explore contributory factors for its development in survivors of CYAC in the U.K. RESEARCH DESIGN AND METHODS: Cancer registration data (n = 4,238) were linked to electronic health care databases to identify cases of diabetes through clinical coding or HbA1c values. Total effect of prespecified treatment exposures on diabetes risk was estimated using flexible parametric modeling and standardized cause-specific cumulative incidence functions (CIFs). RESULTS: After median follow-up of 14.4 years, 163 individuals (3.8%) were identified with diabetes. Total body irradiation (TBI) increases diabetes risk over time, with a 40-year CIF reaching 21.0% (95% CI 13.8-31.9) compared with 8.4% (95% CI 6.1-11.5) without TBI. Survivors treated with corticosteroids had a 7.7% increased risk at 40 years after cancer diagnosis. Hematopoietic stem cell transplant (HSCT) survivors had markedly higher risk, with a 40-year CIF of 19.6% (95% CI 13.4-28.6) versus 8.2% (95% CI 6.0-11.3) for patients who had not undergone HSCT. Among patients who received allogeneic HSCT, the 40-year CIF of diabetes was 25.7% (95% CI 17.4-38.0), compared with 7.9% (95% CI 3.3-19.1) in patients who received autologous transplants. CONCLUSIONS: This evaluation of a hospital-based cohort of patients with CYAC identifies these patients' increased long-term risk of developing diabetes and how this varies temporally according to treatment modalities. Notable contrasts in risk by treatment were detected as early as 10 years after cancer diagnosis. Findings should inform the development of risk-stratified evidence-based screening.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Cromie KJ, Murray RD, Ajjan RA, et al. Diabetes Risk After Treatment for Childhood and Young Adult Cancer. Diabetes Care. 2025. PMID: 39854362. doi:10.2337/dc24-2171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。